Screener
Castle Biosciences CSTL Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
| Income tax expense (benefit) | 109 | (423) |
| Net loss | $(14,522) | $(25,848) |
| Loss per share, basic and diluted | $(0.49) | $(0.90) |
| Weighted-average shares outstanding, basic and diluted | 29,889 | 28,609 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's income tax?
- Castle Biosciences (CSTL) reported income tax of $109K in Q1 2026.
- How has Castle Biosciences's income tax changed year-over-year?
- Castle Biosciences's income tax increased by 125.8% year-over-year, from -$423K to $109K.
- What is the long-term trend for Castle Biosciences's income tax?
- Over 3 years (2021 to 2025), Castle Biosciences's income tax has grown at a -15.0% compound annual growth rate (CAGR), from -$8.72M to -$5.36M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Castle Biosciences's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude